Our Pricing

Why Is Wegovy Dose Lower Than Mounjaro? Understanding Dosage Differences

Many patients ask why Wegovy dose lower than Mounjaro when comparing these two leading weight loss injections. The answer lies in their different active ingredients and mechanisms: Wegovy contains semaglutide with a maximum dose of 2.4mg weekly, whilst Mounjaro contains tirzepatide reaching up to 15mg weekly. These aren't directly comparable milligram-for-milligram because they work through different receptor pathways, and clinical trials demonstrate both achieve significant weight loss at their respective therapeutic doses.

Understanding Why Wegovy Dose Lower Than Mounjaro in Milligrams

The numerical difference in Wegovy dose lower than Mounjaro reflects fundamental differences in molecular structure and potency, not treatment effectiveness. Semaglutide (Wegovy) is a GLP-1 receptor agonist requiring 2.4mg weekly to achieve optimal therapeutic effect, whilst tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist with a maximum maintenance dose of 15mg weekly [1]. These medications cannot be compared by milligram alone because their receptor binding affinities and pharmacokinetic profiles differ substantially.

In the STEP 1 trial, Wegovy at 2.4mg weekly produced an average weight loss of 14.9% over 68 weeks, whilst the SURMOUNT-1 trial showed Mounjaro 15mg achieved 20.9% average weight loss over 72 weeks [2]. However, both medications demonstrate clinical efficacy at their respective licensed doses, and the lower milligram amount in Wegovy does not indicate reduced potency. Our clinical team at Cured Pharmacy frequently explains to patients that dose comparison requires understanding receptor pharmacology, not simple numerical comparison.

The escalation schedules also differ significantly: Wegovy increases from 0.25mg to 2.4mg over 16-20 weeks, whilst Mounjaro escalates from 2.5mg to 15mg over a similar timeframe [3]. This graduated approach minimises gastrointestinal side effects whilst allowing the body to adapt to each medication's mechanism. Patients switching between treatments require careful clinical assessment by our UK-registered prescribers to ensure appropriate dosing transitions.

Wegovy Dose Lower Than Mounjaro: Different Mechanisms Explained

The reason Wegovy dose lower than Mounjaro in numerical terms relates directly to their receptor targeting strategies. Semaglutide activates only GLP-1 receptors with extremely high binding affinity, achieving maximal therapeutic effect at 2.4mg weekly. Tirzepatide activates both GIP and GLP-1 receptors, requiring higher milligram dosing to effectively engage both pathways simultaneously [4].

GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves glycaemic control. Mounjaro's additional GIP receptor activity may enhance fat metabolism and insulin sensitivity beyond GLP-1 alone, potentially explaining the higher average weight loss observed in head-to-head comparisons [5]. However, individual response varies considerably, and some patients achieve excellent results with Wegovy's lower-dose GLP-1-only approach, particularly when gastrointestinal tolerability is a concern.

Receptor Binding and Clinical Efficacy

Despite Wegovy dose lower than Mounjaro numerically, semaglutide demonstrates approximately 95% GLP-1 receptor occupancy at therapeutic doses, representing near-maximal receptor activation [6]. Tirzepatide's dual-agonist design requires higher milligram dosing to achieve balanced GIP and GLP-1 activation, but this doesn't necessarily translate to proportionally greater benefits for all patients. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that treatment selection should consider individual tolerance, medical history, and treatment goals rather than focusing solely on milligram differences.

Should You Switch If Wegovy Dose Lower Than Mounjaro?

Patients often wonder whether switching from Wegovy to Mounjaro makes sense given that Wegovy dose lower than Mounjaro in milligrams. The decision requires clinical assessment considering current weight loss progress, side effect profile, and treatment goals. If you've achieved satisfactory results on Wegovy 2.4mg weekly, switching may not provide additional benefit and could introduce new side effects during the transition period.

Clinical data suggests switching may be appropriate for patients who have plateaued on maximum-dose Wegovy or require additional glycaemic control for type 2 diabetes management [7]. However, transitioning between GLP-1 medications requires careful prescriber supervision to manage the washout period and dose escalation appropriately. At Cured Pharmacy, our UK-registered clinical team conducts thorough assessments before approving any treatment switches, ensuring patient safety and optimal outcomes.

Cost considerations also factor into switching decisions. Wegovy is available from £124.99 at Cured Pharmacy with competitive UK pricing, whilst Mounjaro starts from £124.99 reflecting its dual-agonist formulation. Patients should discuss with their prescriber whether the potential additional weight loss with Mounjaro justifies the higher investment, particularly if Wegovy is already producing meaningful results.

Transition Protocol Between Treatments

When switching from Wegovy to Mounjaro despite Wegovy dose lower than Mounjaro, most prescribers recommend starting Mounjaro at the 2.5mg dose after the final Wegovy injection has cleared (typically 4-5 weeks given semaglutide's half-life). This conservative approach minimises overlapping GLP-1 activity and reduces gastrointestinal side effects. Patients should never combine both medications simultaneously without explicit prescriber approval, as this significantly increases adverse event risk.

Wegovy Dose Lower Than Mounjaro: Safety and Side Effect Profiles

Although Wegovy dose lower than Mounjaro numerically, both medications share similar side effect profiles dominated by gastrointestinal symptoms including nausea, diarrhoea, constipation, and vomiting [8]. These effects typically diminish over time as the body adapts to treatment. Some patients find Wegovy's lower-dose GLP-1-only mechanism better tolerated than Mounjaro's dual-agonist approach, whilst others experience the opposite.

Serious adverse events remain rare with both treatments but include potential pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies). The MHRA and NHS emphasise that both medications require careful patient selection, excluding those with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Our clinical team at Cured Pharmacy conducts comprehensive medical history reviews during the online consultation process to identify any contraindications before prescribing.

The graduated dose escalation with both medications helps mitigate side effects, but the fact that Wegovy dose lower than Mounjaro doesn't necessarily mean fewer adverse events. Individual tolerance varies, and some patients tolerate higher-dose tirzepatide better than lower-dose semaglutide. This underscores the importance of personalised treatment selection under UK prescriber supervision.

Clinical Evidence: Wegovy Dose Lower Than Mounjaro Impact on Results

Direct comparison trials examining whether Wegovy dose lower than Mounjaro affects weight loss outcomes show tirzepatide producing approximately 5-6 percentage points greater average weight loss at maximum doses. The SURMOUNT-1 trial demonstrated 20.9% average weight loss with Mounjaro 15mg versus 14.9% with Wegovy 2.4mg in the STEP 1 trial, though these were separate studies with different populations [2].

However, these averages mask substantial individual variation. Approximately 35% of Wegovy patients achieved ≥20% weight loss in clinical trials, demonstrating that lower milligram dosing doesn't preclude excellent outcomes for many individuals. Treatment response depends on multiple factors including baseline weight, metabolic health, lifestyle modifications, and genetic factors influencing GLP-1 receptor sensitivity.

NICE guidance recognises both medications as clinically effective for weight management in appropriate patients, without favouring one over the other based solely on dose differences. The choice between Wegovy and Mounjaro should consider the complete clinical picture, not just the numerical dose disparity. Our pharmacists help patients understand these nuances during the consultation process, ensuring informed treatment decisions.

Long-Term Weight Maintenance Considerations

Evidence suggests that despite Wegovy dose lower than Mounjaro, both medications require ongoing treatment to maintain weight loss, with significant regain observed after discontinuation [7]. This reflects the chronic nature of obesity and the ongoing metabolic effects of GLP-1 pathway modulation. Patients should view either medication as a long-term commitment rather than a short-term intervention, with treatment duration determined by individual response and tolerability under prescriber guidance.

Accessing Wegovy and Mounjaro: Wegovy Dose Lower Than Mounjaro Price Comparison

Understanding that Wegovy dose lower than Mounjaro helps contextualise the UK pricing landscape. At Cured Pharmacy, Wegovy is available from £124.99 with our competitive pricing guarantee, representing excellent value for a clinically proven GLP-1 treatment. New patients Save £20 off their first order using code Weightlossnew, making treatment initiation more accessible.

Both medications require prescription following online clinical assessment by our UK-registered prescribers. The consultation process takes under 3 minutes and evaluates medical history, current medications, and treatment suitability. We provide transparent upfront pricing before consultation, ensuring patients understand costs before committing to assessment. All medications dispensed are genuine UK-licensed products from registered wholesalers, never grey market imports.

Our discreet packaging and next-day delivery service ensure convenient access to treatment without pharmacy visits. As a GPhC-registered pharmacy (9012511) operating under superintendent pharmacist Tarun Kumar's oversight, we maintain the highest standards of pharmaceutical care whilst offering the lowest prices guaranteed in the UK. Patients can contact our clinical team on (+44) 116 4646009 for any questions regarding treatment selection, dosing, or the differences between Wegovy and Mounjaro.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Wilding, J. P., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. [accessed 15 August 2026]
5. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. [accessed 15 August 2026]
6. Lau, J., et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370-7380. [accessed 15 August 2026]
7. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
8. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Medicines and Healthcare products Regulatory Agency. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.